Neuronetics Partners with ANT Neuro to Enhance TMS Treatment Precision — Neuronetics, Inc.

Event summary

Neuronetics and ANT Neuro announced a strategic partnership on May 14, 2026, to integrate ANT Neuro’s visor2™ neuronavigation system with Neuronetics’ NeuroStar TMS treatment platform.
The collaboration aims to enhance treatment visualization, consistency, and personalization through real-time spatial tracking and 3D visualization.
Neuronetics will offer ANT Neuro’s visor2™ system alongside NeuroStar TMS, enabling healthcare providers to incorporate advanced image-guided navigation technology.
The partnership will be showcased at industry meetings, including the American Psychiatric Association Annual Meeting in May and the Clinical TMS Society Annual Meeting in June, with a broader rollout planned for the second half of 2026.

The big picture

This partnership aligns with the broader industry trend of integrating advanced technologies into mental health treatments to improve precision and outcomes. Neuronetics, with the largest installed base of TMS systems in the U.S., is positioning itself to lead in the evolving TMS market by enhancing treatment visualization and standardization. The collaboration reflects a strategic move to meet the growing demand for sophisticated, personalized treatment workflows in neurohealth.

What we're watching

Market Adoption: How quickly healthcare providers will adopt the integrated NeuroStar TMS and visor2™ system, and whether this will drive significant growth in the TMS market.
Competitive Response: Whether competitors in the TMS space will respond with similar technological enhancements, potentially intensifying market competition.
Regulatory Compliance: The pace at which the integrated system will receive full regulatory approvals and clearances, ensuring seamless market entry and adoption.